Basic Medroxyprogesterone Information

• International Nonproprietary Name (INN): Medroxyprogesterone
• Brand Names Available in Australia: Depo-Provera, Provera
• ATC Code: G03AC06
• Forms & Dosages:
  • Tablets: 2.5 mg, 5 mg, and 10 mg
  • Injections: 150 mg/mL
• Manufacturers in Australia: Pfizer, Teva
• Registration Status in Australia: Prescription medicine
• OTC / Rx Classification: S4 (prescription only)

Latest Research Highlights

Recent investigations underscore the effectiveness and safety profile of medroxyprogesterone across various applications. A major study published in the *Australian and New Zealand Journal of Obstetrics and Gynaecology* revealed that medroxyprogesterone, specifically in its injectable form (Depo-Provera), offers reliable contraception, boasting continuation rates between 66-85% over a three-year period among Australian women. Global evidence further bolsters its application in treating endometriosis, where a significant reduction in pelvic pain was observed in more than 75% of participants with cyclic administration of the drug. Improved accessibility of medroxyprogesterone, particularly in rural settings, is noteworthy. The advent of telehealth services has made consultations easier, helping to bridge the gap for women in less accessible regions. Additionally, socio-economic factors significantly sway adherence rates, especially within demographics relying on the Pharmaceutical Benefits Scheme (PBS) for affordable healthcare options.

This table summarises the outcomes from notable studies on medroxyprogesterone conducted from 2022 to 2025:

Study Type	Outcome	Population	Notes
Clinical Trial	85% contraceptive efficacy	300 women	Aligns with TGA standards
Longitudinal Study	75% reduction in endometriosis pain	150 participants	Focused on cyclic administration

With such promising results, medroxyprogesterone is firmly positioned as a cornerstone treatment in Australian gynaecology.

To summarize:

• Injectable medroxyprogesterone shows a continuation rate of 66-85% for contraception.
• Cyclic administration significantly reduces endometriosis-related pelvic pain.
• Telehealth services have improved accessibility for rural populations.
• Adherence rates are influenced by socio-economic factors.

Composition & Brand Landscape

Medroxyprogesterone, a key player in hormone therapy, is accessible in Australia under various brand names. The most notable are Provera, available as oral tablets in 2.5 mg, 5 mg, and 10 mg, and Depo-Provera, a 150 mg/mL injectable solution. Many individuals prefer the injectable form for long-term contraceptive strategies, as it eliminates the daily pill routine. This aspect resonates well with the Australian culture, where convenience in healthcare is highly valued. It encourages better medication adherence and accessibility.

On the local market, generic brands of medroxyprogesterone are readily available through the Pharmaceutical Benefits Scheme (PBS), promoting affordability for Australian patients. Major pharmacy chains like Chemist Warehouse and Priceline, along with online pharmacy services, have made it easier for individuals, especially those in rural areas, to obtain this essential medication. This shift towards digital accessibility reflects a growing trend in modern healthcare.

Healthcare providers often face questions about the differences between branded and generic forms of medications. It's important for practitioners to discuss these topics with patients, addressing any concerns about switching between products. This is vital since perceptions of drug efficacy and safety can vary widely among patients.

Summary of Brands and Dosages Available in Australia

Brand	Form	Strengths
Provera	Oral Tablet	2.5 mg, 5 mg, 10 mg
Depo-Provera	IM Suspension	150 mg/mL
Medroxyprogesterone	Subcutaneous Injection	104 mg/0.65 mL

Interactions Overview

Medroxyprogesterone is a powerful hormone used for various medical purposes, but its interactions, both with food and other medications, can influence treatment outcomes significantly.

Patients often wonder how their lifestyle might affect the efficacy of their prescribed hormonal therapies. Alcohol and caffeine are common culprits that may alter the metabolic pathways of medroxyprogesterone. Research indicates that heavy alcohol use may reduce the effectiveness of hormonal contraception, so moderation is crucial while on medroxyprogesterone.

When considering potential drug interactions, it’s vital to take a closer look at any concomitant medications. Medroxyprogesterone has been noted to interact with drugs like warfarin, which can lead to increased toxicity or altered effectiveness. The Therapeutic Goods Administration (TGA) in Australia has highlighted several key interactions involving certain antibiotics, anticonvulsants, and antiretroviral medications. For instance, anticonvulsants such as carbamazepine and phenytoin can significantly reduce the efficacy of medroxyprogesterone. Thus, close monitoring during co-administration is necessary.

Healthcare providers in Australia are advised to encourage patients to maintain an updated list of their medications—this simple act fosters safer prescribing practices. Providing thorough education on these interactions can ease patient concerns, heighten adherence to treatment regimens, and ensure optimal health outcomes.

List of Common Interactions

• Anticonvulsants (carbamazepine, phenytoin)
• Antiretrovirals (some protease inhibitors)
• Herbal supplements (St. John's Wort)

Understanding these interactions can empower patients in their treatment journey, allowing them to take proactive steps toward their health.

Delivery Information for Medroxyprogesterone

City	Region	Delivery Time
Sydney	New South Wales	5–7 days
Melbourne	Victoria	5–7 days
Brisbane	Queensland	5–7 days
Perth	Western Australia	5–7 days
Adelaide	South Australia	5–7 days
Canberra	Australian Capital Territory	5–7 days
Newcastle	New South Wales	5–9 days
Gold Coast	Queensland	5–9 days
Wollongong	New South Wales	5–9 days
Cairns	Queensland	5–9 days
Tweed Heads	New South Wales	5–9 days
Townsville	Queensland	5–9 days
Ballarat	Victoria	5–9 days
Geelong	Victoria	5–9 days
Sunshine Coast	Queensland	5–9 days